CCM
IRD

Compton Capital Management’s Opus Genetics IRD Stock Holding History

Compton Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31
Closed -$8K – 152
2017
Q1 		$8K Buy
+31
New +$4.02K ﹤0.01% 141

Other funds holding IRD

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Compton Capital Management's IRD Position: Q2 2017 in Review

Compton Capital Management sold out of Opus Genetics (IRD) in Q2 2017, closing a stake of 31 shares — an estimated $8K sold.

Compton Capital Management first reported a position in IRD in Q1 2017 and held it in 1 quarter. The position peaked at $8K in Q1 2017. 23 funds tracked by Wall St. Rank hold IRD as of Q2 2017.

  • Compton Capital Management reported no remaining Opus Genetics position as of Q2 2017 after selling out during the quarter.
  • Compton Capital Management sold 31 Opus Genetics shares in Q2 2017, an estimated $8K.
  • Compton Capital Management first reported a position in Opus Genetics in Q1 2017 and held it in 1 quarter.
  • Compton Capital Management's Opus Genetics position peaked at $8K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2017.

Based on Compton Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.